The FDA Peptide Vote, Explained: What Actually Happened on July 23-24 — and What Didn't

The Short Version

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met at the agency's headquarters in Silver Spring, Maryland, and voted on seven peptides. It recommended six of them — BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — for addition to the 503A Bulks List, the roster of bulk drug substances that traditional compounding pharmacies may lawfully use. It declined to recommend the seventh, emideltide (also called DSIP).

Every one of those votes was close. And in every case, the committee voted against the recommendation of the FDA's own scientific reviewers, who had examined each substance and concluded that none of the seven should be added.

Within hours, a familiar thing happened. Clinic websites, supplement retailers and social accounts began describing these peptides as "FDA approved," "FDA backed," "unbanned," or "now legal." Some announced they were taking orders.

All of that is wrong. Not exaggerated — wrong. The vote did not approve anything, did not legalize anything, and did not change what any pharmacy may lawfully compound today. It was one advisory step in a regulatory process that has not concluded and has no deadline.

This article explains precisely what the committee did, what it did not do, what FDA's reviewers actually objected to, and — the part almost entirely missing from the coverage — the wide gap between the narrow medical conditions FDA evaluated and the reasons people actually buy these peptides.

What the 503A Bulks List Actually Is

To understand the vote, you need to understand what was being voted on — and it is narrower than most coverage implied.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a traditional compounding pharmacy that wants to compound a drug from a bulk substance generally has three lawful routes. The bulk substance must either:

1. Comply with an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph; or
2. Be a component of an FDA-approved drug; or
3. Appear on a list that FDA develops by regulation — the 503A Bulks List.

Most of the peptides in question satisfy none of those three conditions. They have no USP monograph, they are not components of any approved drug, and they are not on the list. That third route is what the July meeting was about.

The statute requires FDA to consult the Pharmacy Compounding Advisory Committee and the United States Pharmacopeial Convention when developing that list. That consultation is what PCAC provides. It is a required input to FDA's decision — not the decision itself.

The Votes, Substance by Substance

One important caveat before the numbers: as of this writing, FDA had not published official minutes or a transcript of the meeting. Every tally below comes from contemporaneous reporting by outlets that had reporters covering the session. Where those outlets disagree, we say so rather than choosing a number.

Peptide	Reported Vote	Outcome	Indication FDA Reviewed
BPC-157	8–6, 1 abstention	Recommended	Ulcerative colitis
KPV	8–6, 1 abstention	Recommended	Wound healing; inflammatory conditions
TB-500	8–6, 1 abstention	Recommended	Wound healing
MOTS-c	7–5 (abstentions unclear)	Recommended	Obesity; osteoporosis
Semax	8–5 (abstentions unclear)	Recommended	Cerebral ischemia; migraine; trigeminal neuralgia
Epitalon	Disputed — see below	Recommended	Insomnia
Emideltide (DSIP)	6–7, 1 abstention	Rejected	Opioid withdrawal; chronic insomnia; narcolepsy

A note on the Epitalon tally

Public reporting conflicts on this one. Regulatory Focus (RAPS) reported the vote as 7–5 with one abstention. STAT reported 7–4 without an abstention count. Both agree the affirmative side prevailed and Epitalon was recommended.

We are not going to pick one. Until FDA publishes an official record, the exact tally is genuinely unresolved, and a site that presents an unverified number as fact is not a site worth trusting on regulatory questions. We will update this article when the official minutes appear.

A note on BPC-157's two votes

There is a wrinkle that got flattened in most coverage. FDA treated BPC-157 free base and BPC-157 acetate as two distinct bulk drug substances and took separate votes. Both were reported at 8–6.

This is not pedantry. FDA's briefing document noted that the nomination materials were inconsistent about which chemical entity was actually being nominated. A regulatory process is being run on a substance whose precise identity was not consistently specified — which matters enormously for what a pharmacy would actually be permitted to purchase and compound.

The Part Almost Nobody Reported: What FDA Actually Evaluated

This is the most important section of this article, and it is the one thing we would ask you to take away if you read nothing else.

An advisory committee reviewing a bulk substance for the 503A list does not evaluate it in the abstract. It evaluates it against a specific nominated clinical use. FDA's reviewers ask whether there is a genuine clinical need for pharmacies to compound this substance for that purpose, and whether the evidence supports it.

For several of these peptides, the indication FDA reviewed bears almost no resemblance to why people actually take them.

BPC-157: reviewed for ulcerative colitis

BPC-157 is marketed almost universally for injury repair — tendon and ligament healing, post-surgical recovery, joint pain, "the Wolverine stack." It is the single most searched-for peptide in the recovery category.

FDA did not evaluate any of that. It evaluated BPC-157 for ulcerative colitis, an inflammatory bowel disease. Its briefing document expressly noted that it did not assess the substance for tendon healing, general injury repair, Crohn's disease, celiac disease or tendonitis, because the nomination or its supporting evidence was inadequate for those uses.

So when a clinic tells you an FDA advisory committee "backed BPC-157," the honest translation is: a divided committee said there might be a clinical need for pharmacies to compound it for an inflammatory bowel condition, over FDA's objection, and that question is unrelated to your shoulder.

Epitalon: reviewed for insomnia

Epitalon is sold on longevity and anti-aging claims, usually involving telomeres and telomerase. FDA reviewed it for insomnia.

And the agency's objection is worth reading closely: FDA noted that the studies offered focused on melatonin measurements rather than on whether patients actually slept better. It also flagged a potential carcinogenicity concern arising from the proposed telomerase mechanism — that is, the very mechanism marketed as the anti-aging benefit was cited by FDA reviewers as a safety question.

Semax: reviewed for cerebral ischemia, migraine and trigeminal neuralgia

Semax is sold online almost entirely as a nootropic — focus, cognition, memory, ADHD. FDA reviewed it for cerebral ischemia, migraine and trigeminal neuralgia. Cognition was not the question before the committee.

MOTS-c: reviewed for obesity and osteoporosis

MOTS-c is marketed for mitochondrial health, longevity, metabolic optimization and athletic performance. FDA reviewed it for obesity and osteoporosis.

TB-500: reviewed for wound healing

TB-500 is sold to athletes for injury recovery and performance. FDA reviewed it for wound healing — and specifically noted an absence of persuasive in-vivo wound-healing evidence for TB-500 itself, as distinct from full-length thymosin beta-4, of which TB-500 is only a fragment.

The pattern holds across the slate. A favorable recommendation for a narrow indication is being marketed as validation of a much broader set of claims that no one at FDA evaluated.

Why FDA's Own Scientists Said No — to All Seven

It is unusual, though not unprecedented, for an advisory committee to break with the agency's review staff. Here it happened on all seven substances.

FDA's objections were remarkably consistent across the briefing documents, and they were not primarily about whether these peptides "work." They were substantially about whether anyone can say with confidence what is in the vial.

Recurring deficiencies cited across the seven reviews:

• Identity and nomenclature. Inconsistent naming and characterization — in several cases FDA could not consistently determine which chemical entity was being nominated.
• Impurity controls. Missing or inadequate specifications for peptide-related impurities, aggregates, microbial contamination and endotoxin.
• Immunogenicity. Unaddressed risk that the peptide provokes an immune response — a well-known hazard for peptide products.
• Toxicology. No adequate nonclinical toxicology program for most substances.
• Human evidence. Evidence often limited to laboratory and animal studies, or to small, uncontrolled, short-duration or incompletely reported human studies.
• Route of administration. Little or no evidence supporting the specific routes proposed — subcutaneous injection in particular.
• Available alternatives. FDA-approved treatments already exist for essentially every nominated indication.

That last point deserves emphasis, because it is the crux of the legal test. The question is not only "is this substance promising?" but "is there a clinical need for pharmacies to compound it, given what is already approved and available?" FDA's reviewers concluded there was not.

Committee members who voted no echoed those concerns in the room, and several raised a further worry: that appearing on the 503A list would create a false impression among patients that a substance had been vetted to the same standard as an approved drug. Given how the vote was immediately marketed, that concern looks well founded.

The Nominations Had Already Been Withdrawn

Here is a detail that reframes the entire meeting, and it received almost no attention.

The nominations for these peptides had been withdrawn. FDA moved the substances to its "nominated but withdrawn" table in April 2026. The agency proceeded to evaluate them and bring them to the committee on its own initiative.

This also clarifies a widely repeated misconception about "Category 2." These peptides had previously been placed in FDA's interim Category 2 — substances the agency identified as posing significant safety risks. Their removal from that category, following the nomination withdrawals, was reported in some quarters as a green light.

It was not. Removal from Category 2 did not move them to Category 1, did not place them on the 503A Bulks List, and did not authorize compounding. It changed which administrative table they appeared in. As of today they sit in none of the categories that would permit a pharmacy to use them under the interim policy.

The Panel Itself Became a Story

Within a day of the vote, the composition of the committee drew scrutiny from the Associated Press, Reuters and STAT.

Those outlets reported that several voting members had commercial or professional relationships with the peptide industry — including members described as operating or consulting for clinics offering peptide therapies, and at least one reported to own or operate a compounding pharmacy selling compounded products. STAT reported that favorable votes came largely from members appointed under the current Department of Health and Human Services leadership.

Context matters here, and so does restraint. Health Secretary Robert F. Kennedy Jr. has publicly championed peptides and has said FDA improperly reclassified peptides during the previous administration. HHS has said members underwent ethics review.

We want to be careful about what that reporting does and does not establish. It documents relationships. It does not establish that any member violated federal ethics rules, that any relationship was legally disqualifying, or that any particular member's vote was improperly influenced. FDA has not published a member-by-member roll call, so nobody outside the room can currently attribute a specific vote to a specific person — and you should be skeptical of anyone who claims to.

What Has To Happen Before Anything Changes

This is the practical heart of it. A favorable PCAC recommendation is step one of a process that looks like this:

1. FDA completes its own evaluation. The vote is non-binding. FDA can accept the recommendation or reject it. It is unusual for the agency to depart from an advisory committee, but it has happened — and here the committee is the one that departed from FDA.
2. FDA publishes a proposed rule in the Federal Register, identifying substances proposed for inclusion or exclusion and explaining its reasoning.
3. A public comment period opens. Anyone — pharmacies, physicians, manufacturers, patients, trade groups — may submit evidence and scientific or legal objections.
4. FDA reviews the comments and the administrative record.
5. FDA publishes a final rule, or withdraws or modifies the proposal.
6. The final rule takes effect and amends the list at 21 CFR 216.23.

Ordinary Administrative Procedure Act notice-and-comment requirements apply throughout. There is no statutory deadline for any of it. Previous 503A list proceedings have run for years between proposed and final rules.

FDA does have a faster lever available in principle: it can announce an interim enforcement discretion policy, typically through guidance, for substances in Category 1 while evaluation proceeds. But such a policy would not add anything to the list, would not constitute approval, would not create an approved indication, would not bind courts or state regulators, and could be withdrawn. As of this writing, none of these seven peptides is in current Category 1, and no post-vote enforcement policy has been published.

Anyone giving you a confident date for when these peptides "become legal" is guessing.

What This Means If You Are a Patient

Practically speaking, on the day this article was published, nothing changed for you.

• None of these peptides is FDA-approved for any indication.
• None is on the 503A Bulks List.
• None has an FDA-approved prescription or over-the-counter status.
• "Research use only" is a seller's label. It is not authorization for administration to a person, and it carries no assurance of identity, purity or sterility.

If you compete in any sport governed by anti-doping rules, note that BPC-157, TB-500 and MOTS-c are prohibited at all times, in and out of competition. For KPV, Semax, Epitalon and emideltide we could not locate a substance-specific WADA or USADA determination — and you should read that as unknown, not as permitted. Absence from a published list is not clearance; check with your governing body.

If you are considering any of these therapies, the useful questions for a prescriber are unchanged: What is the evidence for this substance, for my condition, by this route? What pharmacy is dispensing it, and what is their 503A or 503B status? What is the certificate of analysis? What are the approved alternatives, and why is this better for me?

What This Means If You Run a Clinic or Pharmacy

The compliance position has not moved. Compounding a substance that is not on the 503A list, has no USP monograph and is not a component of an approved drug carries the same regulatory exposure it did the week before the meeting.

The marketing exposure, however, has increased sharply. Describing any of these peptides as "FDA approved," "FDA cleared," "legalized" or "unbanned" on the basis of this vote is inaccurate. It is the kind of claim that draws FTC attention, state board attention and, increasingly, plaintiff attention.

There is also a supply reality that survives any favorable outcome. Even if a substance eventually reaches the 503A list, a 503A pharmacy remains bound by its statutory conditions, and bulk substances must come from a registered establishment with a valid certificate of analysis. A listing does not conjure a compliant supply chain.

What Comes Next

Two things to watch.

First, FDA's response. The agency now decides whether to propose a rule reflecting the committee's recommendations, propose something narrower, or decline. Its reviewers were unambiguous that they did not support any of the seven, which makes this genuinely uncertain rather than a formality.

Second, the next meeting. FDA has signalled another PCAC session before the end of February 2027 to consider five more peptides: LL-37, GHK-Cu, Dihexa acetate, Melanotan II and PEG-MGF. The exact date had not appeared on FDA's advisory committee calendar as of this writing. GHK-Cu in particular is widely sold in skincare and injectable form, so expect the same cycle of confusion to repeat.

How To Read the Claims You Are About To See

For the next several months, marketing around these six peptides will lean hard on this vote. A short field guide:

If a site says…	The accurate version is…
"FDA approved"	Not approved. No FDA-approved product contains it.
"Now legal to compound"	Not on the 503A list. Rulemaking has not occurred.
"Unbanned by the FDA"	Removal from Category 2 happened earlier and authorized nothing.
"FDA panel endorsed it for healing"	The panel considered a narrow named indication. For BPC-157 that was ulcerative colitis.
"Available soon — pre-order now"	No timeline exists. No statutory deadline applies.

We maintain a continuously updated status page for all seven substances, with the vote, the indication FDA reviewed, current 503A and 503B status, anti-doping status and primary-source links for each: see the FDA 503A peptide compounding tracker. Individual status pages are available for BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon and emideltide.

The Bottom Line

A divided advisory committee, several of whose members have documented ties to the peptide industry, voted narrowly to recommend six peptides for a compounding list, over the objection of FDA's own scientific reviewers, for indications that in several cases have little to do with why the substances are actually sold.

That is a real and newsworthy development. It may eventually change what compounding pharmacies can legally make. It also may not — FDA is not obliged to follow, and its reviewers went zero for seven.

What it definitively did not do is make anything approved, legal, safe, or available. If your decision about a peptide changed because of a headline this week, it changed on the basis of something that has not happened yet.